Drug Profile
Laulimalide
Latest Information Update: 17 Feb 2006
Price :
$50
*
At a glance
- Originator Utah State University
- Developer University of Hawaii; Utah State University
- Class Antineoplastics; Lactones
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Feb 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 31 Dec 2001 This agent is still in active development
- 14 May 1999 New profile